Updated analysis of CALGB 100104 (Alliance): a randomised phase III study evaluating lenalidomide vs placebo maintenance after single autologous stem cell transplant for multiple myeloma

BACKGROUND: CALGB 100104 (Alliance) studied lenalidomide vs. placebo following autologous stem cell transplant (ASCT) for newly diagnosed myeloma patients, demonstrating improved time to progression (TTP) and overall survival (OS), and an increase in second primary malignancies (SPM) for lenalidomid...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Lancet Haematol
Main Authors: Holstein, Sarah A., Jung, Sin-Ho, Richardson, Paul G., Hofmeister, Craig C., Hurd, David D., Hassoun, Hani, Giralt, Sergio, Stadtmauer, Edward A., Weisdorf, Daniel J., Vij, Ravi, Moreb, Jan S., Callander, Natalie S., van Besien, Koen, Gentile, Teresa G., Isola, Luis, Maziarz, Richard T, Bashey, Asad, Landau, Heather, Martin, Thomas, Qazilbash, Muzaffar H, Rodriguez, Cesar, McClune, Brian, Schlossman, Robert L., Smith, Scott E., Hars, Vera, Owzar, Kouros, Jiang, Chen, Boyd, Molly, Schultz, Chelsea, Wilson, Marcia, Hari, Parameswaran, Pasquini, Marcelo C., Horowitz, Mary M., Shea, Thomas C., Devine, Steven M., Linker, Charles, Anderson, Kenneth C., McCarthy, Philip L.
פורמט: Artigo
שפה:Inglês
יצא לאור: 2017
נושאים:
Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC5718627/
https://ncbi.nlm.nih.gov/pubmed/28826616
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2352-3026(17)30140-0
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים